Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

22 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Docetaxel, cisplatin and 5-FU compared with docetaxel, cisplatin and cetuximab as induction chemotherapy in advanced squamous cell carcinoma of the head and neck: Results of a randomised phase II AGMT trial.
Keil F, Hartl M, Altorjai G, Berghold A, Riedl R, Pecherstorfer M, Mayrbäurl B, De Vries A, Schuster J, Hackl J, Füreder T, Melchardt T, Burian M, Greil R. Keil F, et al. Among authors: fureder t. Eur J Cancer. 2021 Jul;151:201-210. doi: 10.1016/j.ejca.2021.03.051. Epub 2021 May 19. Eur J Cancer. 2021. PMID: 34022697 Clinical Trial.
Postoperative chemoradiotherapy with cisplatin is superior to radioimmunotherapy with cetuximab and radiotherapy alone : Analysis of the Austrian head and neck cancer registry of the AGMT.
Magnes T, Wagner SM, Melchardt T, Weiss L, Rinnerthaler G, Huemer F, Kopp M, Gampenrieder SP, Mayrbäurl B, Füreder T, Lenger D, Andel J, Egle A, Greil R. Magnes T, et al. Among authors: fureder t. Wien Klin Wochenschr. 2021 Nov;133(21-22):1131-1136. doi: 10.1007/s00508-021-01939-3. Epub 2021 Sep 15. Wien Klin Wochenschr. 2021. PMID: 34528125 Free PMC article.
Dose study of the multikinase inhibitor, LY2457546, in patients with relapsed acute myeloid leukemia to assess safety, pharmacokinetics, and pharmacodynamics.
Wacheck V, Lahn M, Dickinson G, Füreder W, Meyer R, Herndlhofer S, Füreder T, Dorfner G, Pillay S, André V, Burkholder TP, Akunda JK, Flye-Blakemore L, Van Bockstaele D, Schlenk RF, Sperr WR, Valent P. Wacheck V, et al. Among authors: fureder w, fureder t. Cancer Manag Res. 2011;3:157-75. doi: 10.2147/CMR.S19341. Epub 2011 May 10. Cancer Manag Res. 2011. PMID: 21625399 Free PMC article.
[Therapy of castration-resistant prostate cancer].
Rauchenwald M, Bauernhofer T, De Santis M, Füreder T, Höltl W, Kramer G, Krause S, Loidl W, Oismüller R, Reissigl A, Schmeller N, Stackl W, Stoiber F, Krainer M. Rauchenwald M, et al. Among authors: fureder t. Wien Klin Wochenschr. 2012 Aug;124(15-16):538-51. doi: 10.1007/s00508-012-0206-1. Epub 2012 Jul 20. Wien Klin Wochenschr. 2012. PMID: 22815001 German.
Review of cancer treatment with immune checkpoint inhibitors : Current concepts, expectations, limitations and pitfalls.
Thallinger C, Füreder T, Preusser M, Heller G, Müllauer L, Höller C, Prosch H, Frank N, Swierzewski R, Berger W, Jäger U, Zielinski C. Thallinger C, et al. Among authors: fureder t. Wien Klin Wochenschr. 2018 Feb;130(3-4):85-91. doi: 10.1007/s00508-017-1285-9. Epub 2017 Nov 2. Wien Klin Wochenschr. 2018. PMID: 29098404 Free PMC article. Review.
22 results